Moomoo AIのまとめ
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Avalo Therapeutics, Inc. has been the subject of a Schedule 13G/A amendment filing with the United States Securities and Exchange Commission (SEC) on December 31, 2023. The filing indicates that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Mr. Ortav Yehudai, have reported shared voting and dispositive power over 2,085 shares of Avalo Therapeutics' common stock, which represents 0.26% of the company's class of securities. The shares in question are associated with warrants that are subject to a Beneficial Ownership Cap, preventing the exercise of the warrants if it would result in ownership exceeding 9.99% of the outstanding common stock. The filing, dated February 14, 2024, also includes a joint filing agreement between the reporting persons, indicating their intention to file this statement jointly in accordance with SEC regulations. The reporting persons have disclaimed beneficial ownership of the shares except to the extent of their pecuniary interest, and the filing certifies that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
2023年12月31日、米国証券取引委員会（SEC）に対してスケジュール13G/A修正申請が行われた結果、Avalo Therapeutics, Inc.が対象となりました。申請によれば、Great Point Partners、LLC、Dr. Jeffrey R. Jay、M.D.、およびMr. Ortav Yehudaiは、Avalo Therapeuticsの普通株式共有投票と投票権を2,085株保有しており、同社の証券クラスの0.26％を占めます。対象となる株式には、ベネフィシャルオーナーシップキャップが適用されるワラントが関連しており、所有が発行済み普通株式の9.99％を超える場合、...すべて展開
2023年12月31日、米国証券取引委員会（SEC）に対してスケジュール13G/A修正申請が行われた結果、Avalo Therapeutics, Inc.が対象となりました。申請によれば、Great Point Partners、LLC、Dr. Jeffrey R. Jay、M.D.、およびMr. Ortav Yehudaiは、Avalo Therapeuticsの普通株式共有投票と投票権を2,085株保有しており、同社の証券クラスの0.26％を占めます。対象となる株式には、ベネフィシャルオーナーシップキャップが適用されるワラントが関連しており、所有が発行済み普通株式の9.99％を超える場合、そのワラントの行使が制限されます。2024年2月14日付けの申請書には、申報者間の共同申請契約も含まれており、SEC規制に従い、この声明を共同で提出する意向が明示されています。申報者は、金銭的利益の度合いに応じて自己の有益所有権を否認し、申請書は、株式の取得がAvalo Therapeuticsの支配権を変更または影響を与える目的ではないことを証明しています。
役に立った
役に立たない
この開示の添付ファイルは以下です：